Brief: Disc Medicine Receives Complete Response Letter From FDA For Bitopertin For The Treatment Of EPP
13/02/2026 20:39
Feb 13 (Reuters) - Disc Medicine Inc IRON.O: DISC MEDICINE RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR BITOPERTIN FOR THE TREATMENT OF EPP DISC MEDICINE INC - FDA REQUIRES RESULTS FROM PHASE 3 APOLLO STUDY FOR DECISION DISC MEDICINE INC - PHASE 3 APOLLO STUDY TOPLINE DATA EXPECTED Q4 2026 DISC MEDICINE INC: FDA ACKNOWLEDGED THAT AURORA AND BEACON PROVIDED SUFFICIENT EVIDENCE THAT BITOPERTIN SIGNIFICANTLY LOWERS PPIX DISC MEDICINE INC: EXPECT AN UPDATED FDA DECISION BY MID-2027 DISC MEDICINE INC: PLANS TO REQUEST A TYPE A MEETING TO REVIEW OUR APPROACH WITH FDA Source text: ID:nGNXbxFlMB Further company coverage: IRON.O